Market Overview

GW Pharmaceuticals Shares Jump Following Price Target Raise

Related GWPH
15 Marijuana Stocks To Watch In 2015: Where Are They Now?
Cramer Shares His Thoughts On J C Penney, Walgreens Boots Alliance, JetBlue Airways And GW Pharmaceuticals
GW Pharmaceuticals' (GWPH) CEO Justin Gover on Q1 2016 Results - Earnings Call Transcript (Seeking Alpha)

In a note released Monday morning, Piper Jaffray made a big raise to the price target of GW Pharmaceuticals (NASDAQ: GWPH) from $97 to $147, citing the potential of GW's Epidiolex to treat epilepsy.

The analysts at Piper Jaffray say that the unique safety/CNS profile make the drug an attractive way to treat epilepsy.

Additionally, the analysts noted that they do not believe INSYS Therapeutics will be able to compete on price.

Following the note, shares of GW Pharmaceuticals are up over six percent in the pre-market.

Latest Ratings for GWPH

Nov 2015Roth CapitalAssumesBuy
Aug 2015Morgan StanleyInitiates Coverage onOverweight
Apr 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color News Price Target Analyst Ratings


Related Articles (GWPH)

Get Benzinga's Newsletters